8-K
filed June 8, 2023, 7:59 PM ET
ticker TARA
CIK 0001359931
other material
confidence high
sentiment neutral
materiality 0.10
Protara Therapeutics annual meeting: all proposals approved by shareholders
Protara Therapeutics, Inc.
- Class III directors elected: Shefferman 5.68M for, Flannelly 5.63M, Smith 5.66M; 2.26M broker non-votes each.
- Ratification of Ernst & Young as auditor passed: 8.16M for, 29,326 against, 709 abstentions.
- Advisory vote on named executive officer compensation approved: 5.57M for, 296,338 against, 62,576 abstentions.
- Record date April 11, 2023; 11,307,962 shares outstanding and entitled to vote.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Protara Therapeutics, Inc. shareholders approved Ratification of the selection of Ernst and Young LLP as independent registered public accounting firm at the 2023-06-07 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-07
Exact text from the filing
Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm. The Company’s stockholders ratified the selection by the Company’s Audit Committee of the Board of Ernst and Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The final voting results were as follows: Votes For Votes Against Abstentions 8,155,867 29,326 709
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Protara Therapeutics, Inc. shareholders approved Advisory approval of the compensation of named executive officers at the 2023-06-07 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-07
Exact text from the filing
Proposal 3. Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s definitive proxy statement for the Annual Meeting. The final voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 5,571,777 296,338 62,576 2,255,211
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Protara Therapeutics, Inc. shareholders approved Election of three Class III directors at the 2023-06-07 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-07
Exact text from the filing
Proposal 1. Election of Directors. The Company’s stockholders elected the three persons listed below as Class III directors, each to serve on the Company’s Board of Directors until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results were as follows: Votes For Votes Withheld Broker Non-Votes Jesse Shefferman 5,677,709 252,982 2,255,211 Barry Flannelly, Pharm. D. 5,625,929 304,762 2,255,211 Cynthia Smith 5,663,928 266,763 2,255,211
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.